Cross-Sector entity

Dinesh Patel

Person
5

All 1 tracked stories fall under one category: market-trends. Dinesh Patel is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Dinesh Patel, all published on March 17, 2026.

1 verified story tracked

Last mentioned: Mar 17, 2026

RSS updates
Share

Entity pulse

Recent coverage · Dinesh Patel

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Dinesh Patel

All 1 tracked stories fall under one category: market-trends. Dinesh Patel is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Dinesh Patel, all published on March 17, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Dinesh Patel. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Data Readout

    Anticipated top-line data from the Phase 3 VERIFY clinical trial.

  2. Q4 Earnings

    Scheduled announcement of quarterly financial results and pipeline update.

  3. VERIFY Enrollment

    Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.

  4. J&J Milestone

    Protagonist receives $231M milestone payment for icotrokinra progress.

Stories mentioning Dinesh Patel 1

Healthcare market trends Neutral 5

Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.

2 sources

Source: themarketsdaily.com · tickerreport.com